BioNxt Solutions (XTER:BXT) Short-Term Debt: €3.30 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTER:BXT BioNxt Solutions Inc XTER:BXT
31 GF Score
Price €0.18
! 4 Warning Signs
View Full Analysis

What is BioNxt Solutions Short-Term Debt?

BioNxt Solutions XTER:BXT -9.27% 31 Short-Term Debt is €3.30 Mil as of Mar. 2026. GuruFocus rates XTER:BXT with a GF Score™ of 31/100. The stock has 4 warning signs investors should review.

BioNxt Solutions's Short-Term Debt for the quarter that ended in Mar. 2026 was €3.30 Mil.

BioNxt Solutions's quarterly Short-Term Debt declined from Sep. 2025 (€1.68 Mil) to Dec. 2025 (€1.22 Mil) but then increased from Dec. 2025 (€1.22 Mil) to Mar. 2026 (€3.30 Mil).

BioNxt Solutions's annual Short-Term Debt declined from Dec. 2023 (€3.35 Mil) to Dec. 2024 (€1.83 Mil) and declined from Dec. 2024 (€1.83 Mil) to Dec. 2025 (€1.22 Mil).

BioNxt Solutions Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

BioNxt Solutions Short-Term Debt Related Terms

BioNxt Solutions Short-Term Debt Historical Data

* Premium members only.

The historical data trend for BioNxt Solutions's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioNxt Solutions Short-Term Debt Chart

BioNxt Solutions Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial 2.06 0.43 3.35 1.83 1.22

BioNxt Solutions Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.63 1.67 1.68 1.22 3.30
XTER:BXT
31GF Score
BioNxt Solutions Inc XTER:BXT
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of €3.30 Mil mean?
BioNxt Solutions (XTER:BXT) has a Short-Term Debt of €3.30 Mil as of Mar. 2026.
Is BioNxt Solutions' Short-Term Debt too high?
BioNxt Solutions' current Short-Term Debt is €3.30 Mil. Overall, BioNxt Solutions has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does BioNxt Solutions' Short-Term Debt compare to ZTS?
BioNxt Solutions' Short-Term Debt of €3.30 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Drug Manufacturers company?
A good Short-Term Debt depends on the Drug Manufacturers industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. BioNxt Solutions's current Short-Term Debt is €3.30 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioNxt Solutions stock overvalued right now?
BioNxt Solutions (XTER:BXT) has a current Short-Term Debt of €3.30 Mil. The current Short-Term Debt is €3.30 Mil. BioNxt Solutions' overall GF Score™ is 31/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For BioNxt Solutions (XTER:BXT), the current Short-Term Debt is €3.30 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioNxt Solutions Business Description

Address 1928 Linden Road, Vancouver, BC, CAN, V6M 1E7
BioNxt Solutions Inc is is a bioscience innovator focused on next-generation drug delivery systems. With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, focused on European markets. The company is committed to improving healthcare by delivering precise, patient-centric solutions that enhance treatment outcomes. Its pipeline includes BNT23001, BNT23002, BNT24002, BNT24003, BNT24004. Its geographic areas are Austria, Germany, Switzerland regions.
31GF Score

Get the complete analysis for XTER:BXT

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.18
Price